Alkermes plc. (NASDAQ:ALKS)
| Market Cap | $7.55B+59.4% |
| Revenue (ttm) | $1.75B |
| Net Income | -$351.00K |
| EPS | -$0.01 |
| Shares Out | 168.04M |
| PE Ratio | n/a |
| Forward PE | 33.21 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,080,735 |
| Open | $45.79 |
| Previous Close | $46.18 |
| Day's Range | $44.83 - $46.89 |
| 52-Week Range | $27.00 - $55.67 |
| Beta | 0.23 |
| Analysts | Buy |
| Price Target | $57.74(+28.48%) |
| Earnings Date | Nov 3, 2026 |
About ALKS
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
5 firms rating ALKS in the last 3 months, one vote each. Issuer-paid research is not counted.
$ALKS stock is featured in our Insider Score Rankings, Congress Trading, and Insider Trades datasets.
→ All Stock ListsCongress Trading
Recent trades of ALKS by members of U.S. Congress
| Gilbert CisnerosHouse / D | Purchase$1.00K – $15.00K | Sep 29, 2026 |
| Gilbert CisnerosHouse / D | Purchase$15.00K – $50.00K | Jul 30, 2026 |
| Gilbert Ray CisnerosHouse / D | Purchase$15.00K – $50.00K | Jul 30, 2026 |
| Gilbert Ray CisnerosHouse / D | Purchase$15.00K – $50.00K | Jul 29, 2026 |
Recently reported changes in ALKS holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by ALKS's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
ALKS Estimated quarterly lobbying spending
Source: U.S. Senate LDA
ALKS Revenue by Segment
| Product sales, net | $417.28M | 50.00% |
| VIVITROL | $127.56M | 15.28% |
| ARISTADA and ARISTADA INITIO | $103.90M | 12.45% |
| LYBALVI | $95.90M | 11.49% |
| LUMRYZ | $89.92M | 10.77% |
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New ALKS patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to ALKS from public contracts
Source: USAspending.gov
Bull Case vs Bear Case
AI-generated from ALKS’s recent data — informational, not investment advice
What’s Behind the Score
News check: CEO outlines six clinical readouts, LUMRYZ filing expected, and exclusivity extension for Lybalvi provide multiple near-term catalysts despite pricing headwind on Alixorexton.
Recent Insider Activity
Insider Score Trend Over Time
-42.0 since Aug 21Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
Frequently Asked Questions
ETFs that hold this stock
| MEDX | Horizon Kinetics Medical ETF | 4.81% |
| IBRN | iShares Neuroscience and Healthcare ETF | 4.75% |
| PSCH | Invesco S&P SmallCap Health Care ETF | 4.23% |
| FBT | First Trust NYSE Arca Biotechnology Index Fund | 3.78% |
| TYNE | Direxion Nanotechnology ETF | 3.37% |
| SMCF | Themes US Small Cap Cash Flow Champions ETF | 2.20% |
| XSMO | Invesco S&P SmallCap Momentum ETF | 1.86% |
| TDNA | T. Rowe Price Biotech ETF | 1.79% |
| XBI | State Street SPDR S&P Biotech ETF | 1.55% |
| MNTL | Tema Neuroscience And Mental Health ETF | 1.53% |
| GSC | Goldman Sachs Small Cap Equity ETF | 1.52% |
| FLQS | Franklin U.S. Small Cap Multifactor Index ETF | 1.04% |
Weight is the stock’s share of each fund’s holdings.
